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amyloid A are inversely related to serum bilirubin:
effect-modification by metabolic syndrome
Petronella E Deetman1, Stephan JL Bakker1 and Robin PF Dullaart2*Abstract
Background: Bilirubin has been implicated in cardiovascular protection by virtue of its anti-inflammatory and anti-oxidative
properties. The metabolic syndrome is featured by enhanced low-grade systemic inflammation and oxidative stress. Serum
amyloid A (SAA) impairs anti-oxidative properties of high-density lipoprotein (HDL). We determined relationships
of high sensitive C-reactive protein (hs-CRP) and SAA with bilirubin in subjects with and without metabolic syndrome (MetS).
Methods: Serum total bilirubin, hs-CRP, SAA and homeostasis model assessment- insulin resistance (HOMA-IR)
were documented in 94 subjects with and in 73 subjects without MetS (26 and 54 subjects with type 2 diabetes
mellitus (T2DM), respectively).
Results: Bilirubin was lower in MetS (P = 0.013), coinciding with higher hs-CRP (P < 0.001) and SAA levels (P = 0.002).
In all subjects combined, hs-CRP was inversely related to bilirubin (r = −0.203, P = 0.008), irrespective of the presence of
MetS or T2DM (interaction terms: P≥ 0.75). The inverse relationship of bilirubin with SAA was confined to subjects
without MetS (r = −0.267, P = 0.009). Furthermore, the presence of either MetS or T2DM modified the relationship
of bilirubin with SAA (interaction terms: β = 0.366, P = 0.003 and β = 0.289, P = 0.025, respectively) in age- and sex-adjusted
analyses. Effect modification was also found for HOMA-IR (β = 0.790, P = 0.020). Of the individual MetS components, the
strongest interaction of bilirubin on SAA was observed with low HDL cholesterol (β = 0.435, P < 0.001).
Conclusions: hs-CRP is inversely related to bilirubin, suggesting that low bilirubin is implicated in enhanced low-grade
systemic inflammation. The inverse relationship of SAA with bilirubin was found to be absent in MetS, which could be at-
tributable to MetS-associated abnormalities in HDL characteristics.
Keywords: Metabolic syndrome, Serum amyloid A, BilirubinBackground
Bilirubin has well known anti-oxidative and anti-inflammatory
properties, as evidenced by its ability to scavenge peroxyl
radicals, to inhibit low density lipoprotein (LDL) oxidation
and to downregulate expression of the cellular adhesion
molecules, VCAM-1 and ICAM-1 in vitro [1,2]. During
the past few years the concept is emerging that bilirubin is
involved in the pathogenesis of several disorders featured
by enhanced systemic low-grade inflammation and in-
creased oxidative stress, such as atherosclerotic cardiovas-
cular disease, metabolic syndrome (MetS) and Type 2* Correspondence: r.p.f.dullaart@umcg.nl
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stated.diabetes mellitus (T2DM) [3-8]. Accordingly, isolated
hyperbilirubinemia confers decreased intima media thick-
ness, a marker of subclinical atherosclerosis [9,10]. Con-
versely, low serum bilirubin levels determine increased
intima media thickness [11], increased atherosclerosis se-
verity [12] and higher risk of lower limb amputation in
T2DM [13]. High bilirubin levels were also documented
to predict low cardiovascular and all-cause mortality in
men [14].
In agreement with the notion that higher bilirubin levels
may contribute to reduced systemic low-grade inflamma-
tion, some studies have shown inverse relationships of
high sensitive C-reactive protein (hs-CRP) with serum bili-
rubin [11,15,16]. Little information is, however, available
concerning relationships with other inflammatory markersal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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(SAA), is able to impair anti-oxidative properties of high
density lipoprotein (HDL) [18-20], thereby contributing to
increased oxidative stress. Both hs-CRP and SAA are
established predictors of incident cardiovascular disease
[21-23]. Furthermore, the metabolic syndrome is not only
characterized by lower serum bilirubin, but also by higher
hs-CRP and SAA levels [18,24-26]. In view of the anti-
inflammatory and anti-oxidative properties of bilirubin, as
well as lower bilirubin levels together with higher hs-CRP
and SAA levels in MetS, we decided to test the extent to
which possible relationships of bilirubin with hs-CRP and
SAA are modified by the presence of MetS.
We therefore initiated the present study to establish
relationships of hs-CRP and SAA with bilirubin in sub-
jects with and without MetS.
Methods
Subjects
The medical ethics committee of the University Medical
Center Groningen, The Netherlands approved the study
and all participants provided written informed consent.
This study was performed in a university hospital set-
ting. The subjects (aged > 18 years) were Caucasian, and
were recruited by advertisement in local newspapers. In
total, 167 subjects were included. MetS was defined ac-
cording to the revised National Cholesterol Education
Program-Adult Treatment Panel III (NCEP-ATP III) cri-
teria [27]. Three or more of the following criteria were re-
quired for categorization of subjects with MetS: waist
circumference > 102 cm for men and > 88 cm for women;
blood pressure ≥ 130⁄85 mmHg or use of anti-hypertensive
drugs; fasting plasma triglycerides ≥ 1.70 mmol/l; HDL
cholesterol < 1.0 mmol/l for men and < 1.3 mmol/l for
women; fasting glucose ≥ 5.6 mmol/l. Subjects with
Type 2 diabetes mellitus (T2DM), previously diagnosed
by primary care physicians using guidelines from the
Dutch College of General Practitioners (fasting plasma
glucose ≥ 7.0 mmol/l and/or non-fasting plasma glu-
cose ≥11.1 mmol/l) were allowed to participate. Dia-
betic subjects were treated by primary care physicians
with diet alone or diet in combination with metformin
and/or sulfonylurea. The use of anti-hypertensive medica-
tion was allowed, but the use of insulin was an exclusion
criterion. Further exclusion criteria were clinically mani-
fest cardiovascular disease, current smoking, renal insuffi-
ciency (elevated serum creatinine and/or proteinuria),
thyroid disorders, liver disease, pregnancy, and use of lipid
lowering drugs. Physical examination did not reveal pul-
monary or cardiac abnormalities. All subjects were studied
after an overnight fast. Body mass index (BMI) was calcu-
lated as weight divided by height squared (in kg/m2).
Waist circumference was measured between the 10th rib
and the iliac crest. Insulin resistance was estimated usingthe Homeostasis Model Assessment-Insulin Resistance
(HOMA-IR): glucose (mmol/l) × insulin (mU/l) / 22.5.
Alcohol consumption was estimated with one drink being
assumed to contain 10 grams of alcohol.
Laboratory analyses
Venous blood samples were collected into EDTA-
containing tubes (1.5 mg⁄ml) for measurement of SAA,
hs-CRP and lipids. Serum was obtained for measure-
ment of total bilirubin and transaminases. Plasma and
serum samples were prepared by centrifugation at
1400 g for 15 min at 4°C. Blood glucose and glycated
hemoglobin (HbA1c) levels were measured directly
after blood collection. Samples for other assays were
stored at −80°C until analysis.
Serum total bilirubin was measured by colorimetric assay
with a detection limit of 1.0 μmol/l (2,4-dichloroaniline re-
action; Merck MEGA, Darmstadt, Germany). The inter-
assay coefficients of variation amounts to 3.8% and 2.9%
in the lower normal and higher normal range respectively.
In healthy subjects, bilirubin is most abundantly present in
serum in its unconjugated form [28]. In a validation experi-
ment (n = 80), we observed a strong correlation between
total bilirubin and unconjugated bilirubin (Spearman’s
r = 0.92, p < 0.001), as well as between total bilirubin and
conjugated direct bilirubin (Spearman’s r = 0.82, p < 0.001).
For the present study, we only used serum total bilirubin
in keeping with other reports [29-31].
SAA was measured by a monoclonal antibody-based
sandwich SAA1 enzyme-linked immunosorbent assay
[24,32]. Human apo-SAA was purified from the HDL3
fraction of acute phase serum, linked to helix pomatia
haemocyanin, and injected into Balb/c mice to produce
monoclonal antihuman-SAA antibodies. The antibodies
used are the capture antibody Reu.86.5, which reacts to
all acute phase SAA subtypes and the coupled to horse
radish peroxidase detection antibody Reu.86.1, which re-
acts to the major SAA1 subtype. The assay was stan-
dardized against the international standard for SAA
protein (WHO code 92/680). The inter-assay CV is
7.0%. hs-CRP was assayed by nephelometry with a lower
limit of 0.175 mg/l (BNII N; Dade Behring, Marburg
Germany).
Plasma total cholesterol and triglycerides were assayed
by routine enzymatic methods (Roche/Hitachi cat no.
11875540 and 11876023, respectively; Roche Diagnostics
GmbH, Mannheim, Germany). HDL cholesterol was mea-
sured with a homogeneous enzymatic colorimetric test
(Roche/Hitachi, cat no 04713214; Roche Diagnostics
GmbH, Mannheim, Germany). Low density lipoprotein
(LDL) cholesterol was calculated by the Friedewald
formula. Glucose was analyzed with an APEC glucose
analyzer (APEC Inc., Danvers, MA). HbA1c was measured
by high-performance liquid chromatography (Bio-Rad,
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Serum aminotransferase (ALT) and aspartate amino-
transferase (AST) were measured with pyridoxal phos-
phate activation (Merck MEGA, Darmstadt, Germany).
Standardization was performed according to International
Federation of Clinical Chemistry guidelines.Statistical analysis
SPSS 20 was used for data analysis. Results are expressed
as mean ± SD or as median (interquartile range). Differ-
ences between subjects with and without MetS were de-
termined by unpaired T tests, Mann–Whitney U tests
and Chi-square tests where appropriate. Because of
skewed distribution, logarithmically transformed values
of bilirubin, hs-CRP, SAA and transaminases were used
for linear regression analysis. Univariable relationships
were calculated using Pearson correlation coefficients.
Multivariable linear regression analyses were performed to
determine the independent contribution of bilirubin to
hs-CRP and SAA. Multivariable linear regression analyses
were also carried out to determine interactions of several
variables (i.e. sex, MetS, T2DM and individual MetS com-
ponents) with bilirubin impacting on hs-CRP and SAA.Table 1 Characteristics in 73 subjects with metabolic syndrom
No MetS (n = 94)
Age (years) 56 ± 10
Gender (men/women) 57/37
Alcohol intake (g/day) 4.3 (0–20)
T2DM (yes/no) 26/68
Systolic blood pressure (mm Hg) 131 ± 19
Diastolic blood pressure (mm Hg) 81 ± 10
Waist circumference (cm) 87 ± 11
BMI (kg/m2) 25.0 ± 3.2
Glucose (mmol/l) 6.1 ± 1.4
Insulin (mU/l) 5.3 (4.3-7.8)
HOMA-IR (mU × mmol)/(l2 × 22.5) 1.45 (1.04-2.14)
Total cholesterol (mmol/l) 5.58 ± 0.99
LDL-C (mmol/l) 3.42 ± 0.89
HDL-C(mmol/l) 1.54 ± 0.38
Triglycerides (mmol/l) 1.14 (0.85-1.56)
Total bilirubin (μmol/l) 11 (8–13)
hs-CRP (mg/ml) 1.03 (0.47-2.44)
SAA (mg/l) 1.25 (0.83-1.99)
ALT (U/l) 24 (20–30)
AST (U/l) 25 (22–28)
Data in mean ± SD or in median (interquartile range). ALT: serum aminotransferase;
density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment insulin res
mellitus. *P-value: P-value after adjustment for age, sex and alcohol intake.To this end, the distribution of bilirubin was centered to
its mean value by subtracting the individual value from
the group mean to account for multicollinearity. Inter-
action terms were considered to be statistically significant
at two-sided P-values <0.10, as recommended by Selvin
[33] and by the Food and Drug Administration authorities
[34]. Otherwise, the level of significance was set at two-
sided P-values < 0.05.Results
Seventy-three subjects with MetS and 94 subjects with-
out MetS were enrolled in the study (clinical characteris-
tics shown in Table 1). Significantly more subjects with
MetS had T2DM compared to subjects without MetS.
Oral glucose lowering drugs (sulfonylurea and metfor-
min, either alone or in combination; other glucose low-
ering drugs were not taken) were used by 41 diabetic
subjects with MetS and by 17 diabetic subjects without
MetS (P < 0.001). Twenty-seven subjects with MetS and
seven subjects without MetS used anti-hypertensive
medication (mostly angiotensin-converting enzyme in-
hibitors, angiotensin II antagonists and diuretics, either
alone or in combination; P < 0.001). Estrogens were usede (MetS) and 94 subjects without MetS
MetS (n = 73) P-value P-value*




145 ± 18 <0.001 <0.001
89 ± 9 <0.001 <0.001
104 ± 12 <0.001 <0.001
29.9 ± 4.5 <0.001 <0.001
8.5 ± 2.6 <0.001 <0.001
11.5 (8.6-17.0) <0.001 <0.001
3.96 (2.82-6.80) <0.001 <0.001
5.56 ± 1.00 0.92 0.74
3.31 ± 1.00 0.46 0.59
1.18 ± 0.34 <0.001 <0.001
1.95 (1.67-2.51) <0.001 <0.001
9 (7–11) 0.013 0.009
1.97 (1.31-4.22) <0.001 <0.001
1.76 (1.13-2.83) 0.002 0.027
33 (24–51) <0.001 <0.001
28 (24–33) 0.005 0.044
AST: serum aspartate aminotransferase; BMI: body mass index; HDL-C: high
istance; LDL-C, low density lipoprotein cholesterol; T2DM: Type 2 diabetes
Table 2 Univariable correlations of high sensitive
C-reactive protein (hs-CRP), serum amyloid A (SAA) and
transaminases with bilirubin
hs-CRP SAA
All subjects (n = 167)
hs-CRP 0.612***
Total bilirubin −0.203** −0.112
No MetS (n = 94)
hs-CRP 0.631***
Total bilirubin −0.154 −0.267**
MetS (n = 73)
hs-CRP 0.511***
Total bilirubin −0.155 0.144
No T2DM (n = 87)
hs-CRP 0.655***
Total bilirubin −0.216* −0.227*
T2DM (n = 80)
hs-CRP 0.522***
Total bilirubin −0.161 0.032
No T2DM, No MetS (n = 68)
hs-CRP 0.659**
Total bilirubin −0.203 −0.267*
T2DM , No MetS (n = 26)
hs-CRP 0.587**
Total bilirubin −0.060 −0.403*
No T2DM, MetS (n = 19)
hs-CRP 0.592**
Total bilirubin −0.350 −0.045
T2DM, MetS (n = 54)
hs-CRP 0.489**
Total bilirubin −0.080 0.198
Pearson correlation coefficients are shown. ALT: serum aminotransferase; AST:
serum aspartate aminotransferase; MetS: metabolic syndrome; T2DM: Type 2
diabetes mellitus. Bilirubin, hs-CRP, SAA and transaminases are logarithmically
transformed. *P <0.05; **P <0.01; ***P <0.001.
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postmenopausal women without MetS. Age and sex distri-
bution were not significantly different between subjects with
and without MetS. Blood pressure, waist circumference,
plasma glucose, insulin and HOMA-IR were higher in MetS
subjects (Table 1). Plasma total cholesterol and LDL choles-
terol were not different between the groups. In MetS sub-
jects, triglycerides, hs-CRP, SAA and transaminases were
increased, whereas HDL-C and bilirubin were decreased
(Table 1). These differences remained statistically significant
after adjustment for age, sex, and alcohol intake. In addition,
hs-CRP and SAA were increased in T2DM subjects (1.74
(1.05-4.21) mg/l and 1.72 (1.13-2.57) mg/l) compared to
non-diabetic subjects (1.25 (0.51-2.50) mg/l, P= 0.005 and
1.25 (0.82-1.98) mg/l, P = 0.01, respectively), but bilirubin
was not significantly different between T2DM subjects
(9 (7–12) μmol/l) and non-diabetic subjects 10 (7–14)
μmol/l, P = 0.18).
In the whole study population, there was an inverse
correlation of hs-CRP with bilirubin, whereas similar
trends towards inverse relationships were observed in
subjects with and without MetS or T2DM separately
(Table 2, Figure 1). The relationship of hs-CRP with bili-
rubin, as observed in the whole study, was not different
between men and women (interaction term: β = 0.096,
P = 0.42). This relationship was also not modified by
the presence of either MetS (interaction term: β = −0.051,
P = 0.75) or T2DM (interaction term: β = −0.010, P = 0.94).
Despite a strong relationship between SAA and hs-CRP,
SAA was not significantly correlated with bilirubin in all
subjects together (Table 2). Of note, SAA was inversely re-
lated to bilirubin in subjects without MetS and in subjects
without T2DM (Table 2, Figure 1). An inverse correlation
of SAA with bilirubin was also observed in subjects with-
out MetS and without T2DM, and in subjects without
MetS and with T2DM, but not in subjects with MetS and
without T2DM, and in subjects with both MetS and
T2DM. SAA was unrelated to transaminases, but there
was a positive correlation of hs-CRP with ALT in all sub-
jects combined (r = 0.195, P < 0.05). There was no inter-
action of bilirubin with sex impacting on SAA (interaction
term: β = −0.116, P = 0.34). Furthermore in all subjects
together, bilirubin was inversely correlated with HOMA-
IR (r = −0.204, P = 0.008). On the other hand, hs-CRP
(r = 0.392, P < 0.001) and SAA (r = 0.213, P = 0.006)
were positively correlated with HOMA-IR.
We subsequently determined the extent to which the
relationship of SAA with bilirubin was modified by the
presence of MetS or T2DM. As shown in Table 3, the
presence of MetS interacted with bilirubin on SAA
(model A). The presence of T2DM also interacted with
bilirubin on SAA (model C). Both interaction terms
remained significant after additional adjustment for alco-
hol intake and transaminases (models B and D), oralternatively after adjustment for the use of oral glucose
lowering drugs and anti-hypertensive medication (inter-
action term between MetS and bilirubin: β = 0.373, P =
0.003; interaction term between T2DM and bilirubin:
β = 0.308, P = 0.019; data not shown). In an alternative
analysis with HOMA-IR instead of the presence of
T2DM or MetS, it was found that HOMA-IR inter-
acted with bilirubin on SAA (Table 4, model A), also
after adjustment for alcohol intake and transaminases
(Table 4, model B). Furthermore, in age- and sex-adjusted
analyses, it was observed that bilirubin interacted with low
HDL cholesterol (interaction term: β = 0.440, P < 0.001), el-
evated triglycerides (interaction term: β = 0.289, P = 0.024),
enlarged waist circumference (interaction term: β = 0212,
Figure 1 Relationships of hs-CRP and SAA with bilirubin. Scatterplots showing relationships of high sensitive C-reactive protein (hs-CRP)
(A, B) and serum amyloid (SAA) (C, D) with bilirubin in 73 subjects with MetS (B, D) and 94 subjects without MetS (A, C).
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plasma insulin (interaction term: β = 0.190, P = 0.018), but
not elevated glucose (interaction term: β= 0.091, P= 0.85) or
high blood pressure (interaction term: β=−0.088, P= 0.45)
on SAA (data not shown).Table 3 Multivariable linear regression analyses on the intera
Model A (n = 167) Mode
β P-value β
Age −0.033 0.67 −0.025
Sex (men/women) −0.087 0.26 −0.101
MetS (yes/no) 0.133 0.02 0.118
T2DM (yes/no)
Total bilirubin −0.317 0.011 −0.311
Interaction MetS * total bilirubin 0.336 0.006 0.321




ALT: aminotransferase; AST: aspartate aminotransferase; MetS: metabolic syndrome;
regression coefficient.
Model A: includes age, sex, bilirubin, MetS, T2DM and interaction of MetS with bilir
Model B: additionally includes alcohol intake and transaminases.
Model C: model including age, sex, bilirubin, MetS, T2DM and interaction of T2DM
Model D: additionally includes alcohol intake and transaminases.Discussion
The current study demonstrates that hs-CRP is inversely
related to bilirubin irrespective of the presence of MetS
or T2DM. In view of lower bilirubin and higher hs-CRP
levels in MetS our findings support the possibility thatction of MetS or T2DM with bilirubin on SAA
l B (n = 167) Model C (n = 167) Model D (n = 167)
P-value β P-value β P-value
0.75 −0.045 0.57 −0.033 0.67
0.21 −0.101 0.20 −0.108 0.19
0.16
0.142 0.075 0.085 0.32
0.013 −0.266 0.043 −0.246 0.061
0.009




SAA: serum amyloid A; T2DM: type 2 diabetes mellitus; β: standardized
ubin.
with bilirubin.
Table 4 Multivariable linear regression analyses on the
interaction of HOMA with bilirubin on SAA
Model A (n = 167) Model B (n = 167)
β P-value β P-value
Age −0.034 0.66 −0.027 0.73
Sex −0.099 0.20 −0.097 0.23
Bilirubin −0.097 0.24 −0.099 0.23
HOMA-IR −0.572 0.094 −0.551 0.11




ALT: alanine aminotransferase; AST: aspartate aminotransferase; HOMA:
homeostasis model assessment-insulin resistance; β: standardized
regression coefficient.
Model A: includes age, sex, bilirubin, HOMA and the interaction between
bilirubin and HOMA.
Model B: additionally includes alcohol intake and transaminases.
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grade systemic inflammation in MetS. In univariable
analysis, SAA was inversely correlated with bilirubin in
subjects without MetS, but not in subjects with MetS.
Remarkably, effect modification of the relationship of
SAA with bilirubin was observed in the context of MetS,
T2DM and insulin resistance, despite expected robust
correlations between hs-CRP and SAA levels, which
were present in all subject categories.
Lower bilirubin levels in MetS, and the inverse rela-
tionship of bilirubin with HOMA-IR extend other stud-
ies that reported on such inverse relationships of
bilirubin with abdominal obesity [35], insulin resistance
[36] and diabetes [3,37]. In a large Korean cohort, higher
bilirubin levels were also found to be associated with a
low prevalence of MetS [5]. In agreement with previous
studies, we also found an inverse correlation of hs-CRP
with bilirubin [9,10], which is clearly in line with allegedly
anti-inflammatory properties of bilirubin. Bilirubin is
known to interfere with expression of adhesion molecules
VCAM-1 and ICAM-1 [1], with activity of the complement
system [38] and with T cell differentiation [39]. Hence, it is
conceivable that anti-inflammatory and anti-oxidative ef-
fects of bilirubin may both contribute to less low-grade
chronic inflammation in MetS [3,15,18,25,26,40]. The only
study available so far showed that SAA tended to be lower
in subjects with isolated hyperbilirubinemia due to Gilbert
syndrome compared to healthy individuals [17], suggesting
that high bilirubin levels could be implicated in lower SAA
levels. In the current study, the relationship of SAA with
bilirubin was modified by insulin and HOMA-IR, but not
by elevated glucose. These results, therefore, raise the pos-
sibility that (factors which are closely associated with) insu-
lin resistance, rather than hyperglycemia per se may explainthe absence of a correlation of SAA with bilirubin in insulin
resistant individuals.
Alterations in compositional characteristics of HDL in
MetS are likely to contribute to impaired HDL anti-
oxidative function, as well as to increased systemic oxi-
dative stress [4,19]. MetS is also featured by decreased
levels of the anti-oxidant, paraoxonase-1 [41]. In this re-
gard, it is important that SAA, which is carried on HDL
particles, is able to displace apolipoprotein A-I and
paraoxonase-1 from HDL particles, thereby impairing
the ability of HDL to protect LDL from oxidative modifi-
cation [19,20]. In agreement, we recently observed an in-
verse relationship of HDL anti-oxidative capacity with
SAA in healthy subjects [18]. Of note, such a relation-
ship was found to be absent in MetS [18], in line with
the lack of association of SAA with bilirubin in MetS, as
observed in the current report. Furthermore, we docu-
mented that the positive relationship of total plasma
apolipoprotein E with paraoxonase-1 is absent in MetS
[42]. Taken together, these previous [18,42] and the
present findings would raise the possibility that MetS or
insulin resistance may elicit abnormalities in HDL anti-
oxidative function, which could mask a relationship of
SAA with bilirubin. Indeed, it is noteworthy that of the
individual MetS components the strongest effect modifi-
cation of bilirubin on SAA was observed for HDL chol-
esterol. However, we did not document oxidative stress
in our study population, and consider the present find-
ings regarding the lack of relationship of bilirubin with
SAA in subjects with MetS to be hypothesis generating.
More work is needed to delineate the extent to which
bilirubin may modify the functional properties of HDL
and the proposed role of SAA therein in order to better
understand the protective role of bilirubin in cardiovas-
cular disease [7,8].
Several other methodological issues and limitations of
our study need to be considered. Since we carried out a
cross-sectional study, cause-effect relationships concern-
ing the relationship of hs-CRP and SAA with bilirubin
cannot be ascertained with certainty. Furthermore, data
with respect to physical fitness and a detailed diet
history were not available. The inclusion of T2DM
subjects in the present study allowed us to discern
that the relationship of hs-CRP with bilirubin was
not relevantly modified by the presence of either
MetS or T2DM. In addition, effect modification of
bilirubin on SAA could be demonstrated with respect
to the presence of MetS, T2DM and the degree of in-
sulin resistance.
In conclusion, this study suggests that lower bilirubin
may confer enhanced low-grade systemic inflammation,
as evidenced by higher hs-CRP levels, irrespective of the
presence of MetS. In contrast, the inverse relationship of
SAA with bilirubin was confined to subjects without
Deetman et al. Cardiovascular Diabetology 2013, 12:166 Page 7 of 8
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malities in HDL characteristics.
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